Assessment of automated high-throughput serological assays for prediction of high-titer SARS-CoV-2 neutralizing antibody.
CLIA
CMIA
COVID-19
EIA
IgA
IgG
Neutralization assay
Neutralizing antibody
RT-PCR
SARS-CoV-2
Journal
Journal of clinical virology plus
ISSN: 2667-0380
Titre abrégé: J Clin Virol Plus
Pays: England
ID NLM: 9918283581506676
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
20
01
2021
revised:
08
03
2021
accepted:
20
04
2021
entrez:
9
3
2022
pubmed:
10
3
2022
medline:
10
3
2022
Statut:
ppublish
Résumé
COVID19 convalescent patient plasma units with high titer neutralizing antibody can be used to treat patients with severe disease. Therefore, in order to select suitable donors, neutralizing antibody titer against SARS CoV-2 needs to be determined. Because the neutralization assay is highly demanding from several points of view, a pre-selection of sera would be desirable to minimize the number of sera to be tested. In this study, a total of 140 serum samples that had been titrated for SARS-CoV-2 neutralizing antibody by microneutralization assay were also tested for the presence of anti-SARS-CoV2 antibody using 5 different tests: Architect® immunoassay (Abbott Diagnostics), detecting IgG against the nucleocapsid protein, LIAISON XL® (Diasorin) detecting IgG against a recombinant form of the S1/S2 subunits of the spike protein, VITROS® (Ortho Clinical Diagnostics), detecting IgG against a recombinant form of the spike protein, and ELISA (Euroimmun AG), detecting IgA or IgG against a recombinant form of the S1 subunit. To determine which immunoassay had the highest chance to detect sera with neutralizing antibodies above a certain threshold, we compared the results obtained from the five immunoassays with the titers obtained by microneutralization assay by linear regression analysis and by using receiver operating characteristic curve and Youden's index. Our results indicate that the most suitable method to predict sera with high Nab titer is Euroimmun® IgG, followed closely by Ortho VITROS® Anti-SARS-CoV-2 IgG.
Identifiants
pubmed: 35262004
doi: 10.1016/j.jcvp.2021.100016
pii: S2667-0380(21)00008-9
pmc: PMC8093006
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100016Informations de copyright
© 2021 The Author(s).
Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
Viruses. 2020 Nov 27;12(12):
pubmed: 33260809
Immunobiology. 2020 Nov;225(6):152008
pubmed: 33130519
Transfus Apher Sci. 2020 Jun;59(3):102790
pubmed: 32345485
Euro Surveill. 2020 Jun;25(24):
pubmed: 32583766
mBio. 2020 Oct 16;11(5):
pubmed: 33067385
Front Immunol. 2020 Nov 30;11:611337
pubmed: 33329607
J Clin Invest. 2020 Apr 1;130(4):1545-1548
pubmed: 32167489
Hum Vaccin Immunother. 2021 Jan 2;17(1):84-87
pubmed: 32678695
Am J Clin Pathol. 2020 Aug 5;154(3):293-304
pubmed: 32583852
Vox Sang. 2021 Jan;116(1):136-137
pubmed: 32324899
Rev Med Virol. 2021 May;31(3):e2181
pubmed: 33152146
J Virol Methods. 2022 Jan;299:114327
pubmed: 34644588
Semin Immunol. 2020 Aug;50:101422
pubmed: 33262067
JAMA Intern Med. 2020 Oct 1;180(10):1362
pubmed: 32808969
J Clin Microbiol. 2020 Dec 17;59(1):
pubmed: 33020186
Nature. 2020 Aug;584(7821):450-456
pubmed: 32698192
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Biom J. 2008 Jun;50(3):419-30
pubmed: 18435502
J Med Virol. 2020 Sep;92(9):1475-1483
pubmed: 32356910
Emerg Infect Dis. 2020 Aug;26(8):1842-1845
pubmed: 32459984
JAMA. 2020 Apr 28;323(16):1582-1589
pubmed: 32219428
Science. 2021 Mar 12;371(6534):1152-1153
pubmed: 33514629
Lancet Infect Dis. 2020 Dec;20(12):1350-1351
pubmed: 32979317
Trends Immunol. 2020 Dec;41(12):1100-1115
pubmed: 33132005
Cochrane Database Syst Rev. 2020 Jul 10;7:CD013600
pubmed: 32648959
J Virol. 2014 Dec;88(23):13769-80
pubmed: 25231316
Front Immunol. 2018 Mar 02;9:323
pubmed: 29552008
Trials. 2020 Jun 8;21(1):499
pubmed: 32513308
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496
pubmed: 32253318
Clin Infect Dis. 1995 Jul;21(1):150-61
pubmed: 7578724
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220
Nature. 2020 Dec;588(7839):682-687
pubmed: 33045718
Transfus Med. 2021 Jun;31(3):167-175
pubmed: 33333627
BMJ. 2020 Oct 22;371:m3939
pubmed: 33093056
JAMA. 2020 Aug 4;324(5):460-470
pubmed: 32492084
Nat Commun. 2020 Sep 17;11(1):4704
pubmed: 32943637
Front Immunol. 2020 Aug 07;11:1949
pubmed: 32849654
EBioMedicine. 2020 Dec;62:103101
pubmed: 33160207
Nature. 2021 May;593(7857):130-135
pubmed: 33684923
JAMA. 2020 Apr 28;323(16):1561-1562
pubmed: 32219429